Approach to The Newborn Infant with Dysmorphic Findings and Genetic Counseling: A Comprehensive Review

Dysmorphic Infant Evaluation

Abstract

Background: Congenital anomalies affect approximately 3-5% of live births and are leading causes of perinatal mortality and long-term morbidity. Dysmorphic findings often provide the earliest clinical clues to underlying genetic, chromosomal, or syndromic disorders. This review aims to present a contemporary, evidence-based framework for the evaluation of infants with dysmorphic features, integrating clinical assessment, genetic testing, artificial intelligence tools, and genetic counseling.

Materials and Methods: A comprehensive literature search was conducted in PubMed, Scopus, and Web of Science databases for articles published between 2015 and 2026 using keywords: "dysmorphic features," "congenital anomalies," "newborn," "genetic testing," "CMA," "WES," "WGS," "Face2Gene," and "genetic counseling." Priority was given to systematic reviews, meta-analyses, clinical guidelines, and original research from the last five years. A total of 38 key references were selected for inclusion.

Results: The initial approach to a dysmorphic newborn involves a five-step protocol: stabilization, anomaly screening, detailed history, phenotyping, and stepwise testing. Chromosomal microarray analysis (CMA) is recommended as the first-tier test, with a diagnostic yield of 12-15%. Whole-exome sequencing (WES) adds 20-60% diagnostic yield in CMA-negative cases, and whole-genome sequencing (WGS) is emerging as a comprehensive option. Artificial intelligence tools such as Face2Gene assist in syndrome recognition, with Top-3 accuracy of 77% in diverse populations. Genetic counseling must be provided pre- and post-test, addressing recurrence risks (de novo <1%, autosomal dominant 50%, autosomal recessive 25%, X-linked variable) and variants of uncertain significance (VUS). In populations with high consanguinity, recessive disorders require special attention.

Conclusions: A structured approach combining meticulous phenotyping, early genomic testing, and family-centered genetic counseling significantly improves diagnostic yield and clinical outcomes. CMA remains the first-tier test, followed by trio WES/WGS as needed. AI-assisted facial analysis is a supportive tool, not a replacement for clinical expertise. Newborn genomic screening holds promise but requires careful ethical consideration.